AI Article Synopsis
- Belantamab mafodotin (belamaf) is a newly approved treatment for adults with relapsed/refractory multiple myeloma who have undergone at least four previous therapies, acting as a targeted therapy that binds to BCMA and kills myeloma cells.
- The drug works through multiple mechanisms and its potential benefits have prompted studies to combine belamaf with other cancer treatments.
- The DREAMM-5 trial is currently investigating the safety and effectiveness of belamaf in combination with new agents like GSK3174998, feladilimab, nirogacestat, and dostarlimab compared to using belamaf alone.
Article Abstract
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2020-1269 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!